source
- Eli Lilly licenses Hanmi's GLP-2 asset for $75 million upfrontEli Lilly has signed a licensing agreement with South Korean biotech Hanmi to acquire rights to a GLP-2 drug candidate, paying an upfront cash payment of $75 million. The deal marks Lilly's entry…
- RallyBio pursues second reverse merger, this time with cancer drug developer Avenzo TherapeuticsRallyBio announced on Monday that it will merge with cancer-focused Avenzo Therapeutics in a reverse‑merger transaction. The combined entity will operate under the Avenzo Therapeutics name. The de…